Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Long-Term Debt Repayments: 2014-2024

Historic Long-Term Debt Repayments for Seres Therapeutics (MCRB) over the last 6 years, with Dec 2024 value amounting to $127.9 million.

  • Seres Therapeutics' Long-Term Debt Repayments was N/A to $127.9 million in Q3 2024 from the same period last year, while for Sep 2024 it was $183.6 million, marking a year-over-year change of. This contributed to the annual value of $127.9 million for FY2024, which is 141.97% up from last year.
  • According to the latest figures from FY2024, Seres Therapeutics' Long-Term Debt Repayments is $127.9 million, which was up 141.97% from $52.9 million recorded in FY2023.
  • Seres Therapeutics' 5-year Long-Term Debt Repayments high stood at $127.9 million for FY2024, and its period low was $948,000 during FY2021.
  • Moreover, its 3-year median value for Long-Term Debt Repayments was $52.9 million (2023), whereas its average is $60.9 million.
  • Data for Seres Therapeutics' Long-Term Debt Repayments shows a peak YoY spiked of 2,671.89% (in 2023) over the last 5 years.
  • Yearly analysis of 4 years shows Seres Therapeutics' Long-Term Debt Repayments stood at $948,000 in 2021, then skyrocketed by 101.16% to $1.9 million in 2022, then soared by 2,671.89% to $52.9 million in 2023, then skyrocketed by 141.97% to $127.9 million in 2024.